through genome-wide data and CMAP analysis identified MC-262 as a potential targeted therapy for head and neck squamous cell carcinoma (HNSCC), and its potential target in HNSCC is proliferating cell nuclear antigen (32). This evidence concerns the gene PCNA and head and neck squamous cell carcinoma.